Long-Duration Response to Levodopa in the PPMI-Cohort

Area of Science:

• Neurology
• Pharmacology

Background:

• Levodopa treatment for Parkinson's disease (PD) provides symptom relief but its long-duration levodopa response (LDR) has not been extensively studied.
• A decline in LDR is suspected to correlate with motor complications in PD, yet long-term data is limited.

Purpose of the Study:

• To investigate the temporal changes and clinical significance of the LDR in Parkinson's disease patients.
• Utilize data from the Parkinson's Disease Progression Marker Initiative (PPMI) for comprehensive analysis.

Main Methods:

• Predicting Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III) scores using mixed linear models (MLM) in untreated PD patients.
• Calculating LDR and short-duration response from longitudinal data of initially therapy-naïve PD patients.
• Analyzing symptom progression through correlation and MLM.

Main Results:

• The LDR constituted approximately 50% of the total levodopa response in patients exhibiting LDR.
• No significant alterations in LDR magnitude were detected over a 10-year period.
• Absence of LDR was associated with more rapid motor and non-motor symptom progression in PD patients.

Conclusions:

• The LDR represents a consistent aspect of levodopa's effect in PD and should be factored into clinical trial designs.
• Findings suggest that a decreasing LDR is unlikely to be the primary cause of motor fluctuations in PD.
• The presence of LDR may indicate a slower disease progression trajectory.